Investor Relations

Investors

Investor Relations

Corporate Profile

Anpac Bio is a biotechnology company focusing on early cancer screening and detection and marketing a suite of cancer detection tests, including CDA (cancer differentiation analysis), bio-chemistry, immunology, and genomics tests. Anpac has developed a multi-cancer screening and detection test that uses innovative, patented CDA technology and proprietary cancer-detection device.

Press Releases

Sep 03, 2021

AnPac Bio Increases Ownership Percentage of its Subsidiary AnPai Healthcare from 20% to 60%

PHILADELPHIA, Sept. 03, 2021 (GLOBE NEWSWIRE) -- AnPac Bio-Medical Science Co., Ltd. (“AnPac Bio,” the “Company” or “we”) (NASDAQ: ANPC), a biotechnology company with operations in the United States and China, today announced that its subsidiary, Anpac Bio-Medical Science (Lishui) Co., Ltd.

Aug 30, 2021

AnPac Bio’s USA Laboratory Receives Accreditation from the College of American Pathologists

PHILADELPHIA, Aug. 30, 2021 (GLOBE NEWSWIRE) -- AnPac Bio-Medical Science Co., Ltd. (“AnPac Bio,” the “Company” or “we”) (NASDAQ: ANPC), a biotechnology company with operations in the United States and China, today announced that its Philadelphia, PA Clinical Laboratory Improvement Amendments

Aug 23, 2021

AnPac Bio Successfully Completes Major PreClinical Study, Files with National Medical Products Administration (NMPA) for Registration Testing of Its Multi-Cancer CDA Device

PHILADELPHIA , Aug. 23, 2021 (GLOBE NEWSWIRE) -- via Investor Wire – AnPac Bio-Medical Science Co., Ltd. (“ AnPac Bio,” the “Company” or “we”) (NASDAQ: ANPC), a biotechnology company with operations in the United States and China , today announces that the Company filed with China’s National